- Conditions
- Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
- Interventions
- NIO752, Placebo
- Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 41 Years to 81 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Englewood, Colorado • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 1:08 AM EDT